When was Cellanome founded?

Cellanome was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Cellanome located?

Cellanome is headquartered in Palo Alto, United States.

How many employees does Cellanome have?

As of Sep 30, 2026, the latest employee count at Cellanome is 136.

Is Cellanome a funded company?

Cellanome is a funded company, having raised a total of $119M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 05, 2021.

When was the latest funding round of Cellanome?

Cellanome's latest funding was a $***** Series B round on Dec 23, 2025, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.64B in funding in 2026 to date.

Where does Cellanome rank among its competitors?

Cellanome ranks 6th amongst 922 active competitors, of which 101 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Cellanome, which secured $75.9M in Dec, 2025.

Who are the top competitors of Cellanome?

Cellanome's top competitors include Strand Life Sciences, BGI and Novogene Corporation. Among them, Cellanome secured the most recent funding round in December, 2025.

Cellanome - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of the omic data platform for researchers. The company has developed a multi-omics platform that uses synthetic biology and informatics methods.

Website: www.cellanome.com/
Email ID: *****@cellanome.com

Key Metrics

Founded Year

2020

Location

Palo Alto, United States

Stage

Series B

Total Funding

$119M in 3 rounds

Latest Funding Round

Series B, Dec 23, 2025, $*****

Investors

DFJ Growth & 6 more

Ranked

6^th among 922 active competitors

Employee Count

136 as on Sep 30, 2026

Similar Companies

Strand Life Sciences & 352 more

View Cellanome's full profile

Cellanome has raised a total funding of $119M over 3 rounds. Its first funding round was on Oct 05, 2021. Cellanome has 7 institutional investors.

Here is the list of recent funding rounds of Cellanome:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 23, 2025	2473458	Series B	5338783	4219373	2543578	7760839
Mar 21, 2023	6906237	Series A	3883864	1042283	8637985	3936618
Oct 05, 2021	1579675	Seed	1592466	5667556	3703006	8786332

Access funding benchmarks and valuations. Sign up today!

View details of Cellanome's funding rounds and investors

The founders of Cellanome is Mostafa Ronaghi.

Here are the details of Cellanome's key team members:

Mostafa Ronaghi: Co-Founder of Cellanome and founder of 3 other companies, ParAllele BioScience, GRAIL and NextBio. They are also an angel investor in 4 startups.

View details of Cellanome's Founder profiles and Board Members

Cellanome's employee count trend

Cellanome has 136 employees as of Sep 26. Here is Cellanome's employee count trend over the years:

Uncover Cellanome's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellanome include Strand Life Sciences, BGI and Novogene Corporation. Here is the list of Top 10 competitors of Cellanome, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, WestBridge Capital & 92 others	69/100
2nd	BGI 1999, Shenzhen (China), Public	Provider of services in genome sequencing	-	Sequoia Capital China, Yunfeng Capital & 15 others	66/100
3rd	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
4th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Two Sigma Ventures & 10 others	64/100
5th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
6th	Cellanome 2020, Palo Alto (United States), Series B	Developer of the omic data platform for researchers	$119M	DFJ Growth, Premji Invest & 5 others	59/100
7th	Replay 2021, San Diego (United States), Acquired	Provider of genomic reprogramming platform for writing and delivering big DNA	$55M	OMX Ventures, KKR & 6 others	58/100
8th	Singular Genomics 2016, San Diego (United States), Acquired	Provider of next-generation gene sequencing and multi-omics technologies	-	Perceptive Advisors, Domain Associates & 5 others	58/100
9th	Intus Bio 2014, Farmington (United States), Seed	Developer of sequencing technology for microbiome testing, pathogen identification, and tracking	$4.14M	Design Technologies, Connecticut Innovations ... & 4 others	56/100
10th	Enara Bio 2016, Oxford (United Kingdom), Series B	Developer of T-cell based cancer-cell interface for therapeutics	$84.1M	SV Health Investors, M Ventures & 36 others	54/100